한국어
English
日本語
中文(简体)
Brukinsa Capsule 80 mg (Zanubrutinib)
80mg
Hard capsule · Prescription medication
Biwon Medicine Korea Co., Ltd.
Zanubrutinib acts as a targeted anticancer drug used in the treatment of blood cancers.
MFDS ingredient code M281881
Zanubrutinib is an anticancer component belonging to the class of Bruton tyrosine kinase inhibitors. It is primarily used for the treatment of certain blood cancers, such as non-Hodgkin lymphoma. It is included in medications for the purpose of inhibiting the growth and survival of cancer cells.
Zanubrutinib selectively blocks the enzyme called Bruton tyrosine kinase within cancer cells. When this enzyme is activated, cancer cells proliferate and survive; by inhibiting this, it prevents the growth of cancer cells. As a result, cancer cells die or their proliferation slows down.
Approved uses differ by product. Check each product's information for its actual use.
Zanubrutinib has higher selectivity compared to other Bruton tyrosine kinase inhibitors, resulting in relatively fewer side effects and stable blood concentration maintenance. This features enhances the therapeutic effect while improving patient tolerance.
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Even with the same ingredient, dosage and approved uses can differ by strength, dosage form and combined ingredients. Check each product's information before taking it.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
Product approval information is based on drug information provided by the Ministry of Food and Drug Safety.
Ingredient and class descriptions are not part of MFDS data and were written separately by Cashdoc.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.